Catalyst Brief

← Calendar

PDUFAin 119d

Aquestive Therapeutics, Inc. — Anaphylm (dibutepinephrine)

FDA PDUFA goal date for Class 2 resubmission of Anaphylm sublingual film NDA.

Date
Mar 16, 2027
Type
PDUFA
Ticker
AQST
Indication
Severe allergies / anaphylaxis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.